This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.

Abstract Details

Activity Number: 18
Type: Topic Contributed
Date/Time: Sunday, August 1, 2010 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract - #306838
Title: Better Learning About the MTD in Phase I Oncology Trial: A Case Study Implementing Bayesian Design Based on Continuous Reassessment Method
Author(s): Inna Perevozskaya*+
Companies: Pfizer Inc.
Address: 500 Arcola Rd, Collegeville, PA, 19426,
Keywords: maximum tolerated dose ; phase 1 trials ; oncology ; continual reassessment method ; toxicity ; Bayesian methods

We review a continual Reassessment Method (CRM) design implemented for Phase I trial in oncology, which is currently on-going. A modification of CRM method targeting pre-specified toxicity rate is used. Similar to the traditional 3+3 designs used in oncology Phase 1 trials, learning about drug's toxicity profile occurs in real time. However, this design is expected to greatly improve our ability to learn about the dose-toxicity profile and to identify the correct maximum tolerated dose because it utilizes all available toxicity information via Bayesian approach, including those toxicities that occur after the initial follow-up period; with appropriate choices of design parameters, the overall proportion of toxicities experienced can stay within acceptable limit. We will present operating characteristics of the design with some examples and discuss alternative design options considered.

The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.

Back to the full JSM 2010 program

2010 JSM Online Program Home

For information, contact or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.